
KYTX Stock Forecast & Price Target
KYTX Analyst Ratings
Bulls say
Kyverna Therapeutics Inc. is seeing increased confidence in its lead product, KYV-101, particularly regarding its applicability in the treatment of myasthenia gravis (MG) and potentially beyond, supported by expert insights. The company's probability of regulatory approval for KYV-101 has been raised, reflecting stronger expectations for the product's durability and efficacy demonstrated in compassionate-use cases, along with positive indications in refractory rheumatoid arthritis (RA) and early signals in multiple sclerosis (MS). Additionally, recent data support KYV-101's competitive position in the market, indicating its potential to outperform existing therapies, thereby enhancing the company's long-term growth prospects.
Bears say
Kyverna Therapeutics Inc faces significant risks that contribute to a negative outlook on its stock, primarily due to the lack of durable responses observed in patients treated with its lead product candidate, KYV-101, in lupus nephritis (LN) and myasthenia gravis (MG). Additionally, the potential failure to generate positive data for KYV-101 in stiff person syndrome (SPS) raises concerns about the viability of its key products. Furthermore, the threat of long-term dilution risk adds an additional layer of uncertainty regarding the company's financial health and future performance.
This aggregate rating is based on analysts' research of Kyverna Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
KYTX Analyst Forecast & Price Prediction
Start investing in KYTX
Order type
Buy in
Order amount
Est. shares
0 shares